Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Transactions
Holdings
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Asset disposition
Quarterly results
Acq. announced
Director departure
Appointed director
CC transcript
Notes have priced
Inv. presentation
LIGAND PHARMACEUTICALS INC (LGND) Create: Alert

All | News | Filings
Date FiledTypeDescription
09/27/2023 8-K Quarterly results
08/08/2023 8-K Quarterly results
Docs: "Ligand Reports Second Quarter 2023 Financial Results Conference Call Begins at 4:30 p.m. Eastern Time Today"
06/09/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
05/04/2023 8-K Quarterly results
Docs: "Ligand Reports First Quarter 2023 Financial Results 2023 Financial Guidance Raised Conference Call Begins at 4:30 p.m. Eastern Time Today"
03/13/2023 8-K Other Events  Interactive Data
02/22/2023 8-K Quarterly results
Docs: "Ligand Reports Fourth Quarter and Full Year 2022 Financial Results 2023 Financial Guidance Raised Conference Call Begins at 4:30 p.m. Eastern Time Today"
12/14/2022 8-K Quarterly results
12/05/2022 8-K Quarterly results
11/07/2022 8-K Quarterly results
Docs: "Ligand Reports Third Quarter 2022 Financial Results"
11/04/2022 8-K Quarterly results
10/03/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549",
"Ligand Announces Record Date and Details for Distribution for OmniAb Spin-Off"
09/30/2022 8-K Quarterly results
08/08/2022 8-K Quarterly results
08/02/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
06/29/2022 8-K Quarterly results
06/21/2022 8-K Quarterly results
06/10/2022 8-K Quarterly results
05/04/2022 8-K Quarterly results
03/24/2022 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "Agreement and Plan of Merger, dated as of March, 23, 2022, by and among Avista Public Acquisition Corp. II, Ligand Pharmaceuticals Incorporated, OmniAb, Inc. and Orwell Merger Sub Inc",
"Separation and Distribution Agreement, by and among Avista Public Acquisition Corp. II, Ligand Pharmaceuticals Incorporated and OmniAb, Inc",
"Sponsor Insider Agreement, by and among OmniAb, Inc., Avista Public Acquisition Corp. II and the other parties signatory thereto",
"Amended and Restated Forward Purchase Agreement, by and among Avista Public Acquisition Corp. II, Avista Acquisition LP II and OmniAb, Inc",
"Employee Matters Agreement, by and among Ligand Pharmaceuticals Incorporated, Avista Public Acquisition Corp. II, OmniAb, Inc. and Orwell Merger Sub Inc"
03/23/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549",
"Ligand to Spin-Off its OmniAb Business Through Merger with Avista Public Acquisition Corp. II",
"Investor Presentation, issued March 23, 2022",
"Transcript of Investor Presentation Audio, issued March 23, 2022"
02/17/2022 8-K Quarterly results
Docs: "Ligand Reports Fourth Quarter and Full Year 2021 Financial Results Conference Call Begins at 4:30 p.m. Eastern Time Today"
01/27/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
01/14/2022 8-K Termination of a Material Definitive Agreement  Interactive Data
11/09/2021 8-K Quarterly results
Docs: "Ligand Reports Third Quarter 2021 Financial Results"
08/16/2021 8-K Quarterly results
07/29/2021 8-K Quarterly results
Docs: "Ligand Reports Second Quarter 2021 Financial Results Conference Call Begins at 4:30 p.m. Eastern Time Today"
07/21/2021 8-K Other Events  Interactive Data
07/14/2021 8-K Quarterly results
06/04/2021 8-K Quarterly results
05/03/2021 8-K Quarterly results
02/03/2021 8-K Quarterly results
01/28/2021 8-K Entry into a Material Definitive Agreement, Departure of Directors or Certain Officers; Election of Directors; Appointment of...
12/21/2020 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Ligand and GSK Enter Global Collaboration and License Agreement Leveraging Icagen’s Discovery Technology to Target Neurological Disorders Ligand Group is eligible to receive an upfront payment of $7 million and potential milestone payments and fees of up to $154.5 million and tiered royalties"
12/16/2020 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy